The American Journal of Medicine
Volume 122, Issue 3 , Pages 215-221 , March 2009

The Management of Hyperkalemia in Patients with Cardiovascular Disease

  • Apurv Khanna, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Apurv Khanna, MD, Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-3940
    • ,
  • William B. White, MD

  • Image Result

    Life-threatening ECG changes in hyperkalemia. a, Tented T waves, loss of P waves, and a wide QRS complex in a patient presenting with paralysis and acute renal failure (serum K+=9.3 mmol/L). b, Sine-w

    Life-threatening ECG changes in hyperkalemia. a, Tented T waves, loss of P waves, and a wide QRS complex in a patient presenting with paralysis and acute renal failure (serum K+=9.3 mmol/L). b, Sine-wave pattern in a patient with acute renal failure and digoxin toxicity (serum K+=9.3 mmol/L). c, Severe bradycardia at a rate of 28 beats/min in a patient on hemodialysis presenting with syncope (serum K+= 8.1 mmol/L). d, Ventricular tachycardia in a patient on hemodialysis presenting with generalized weakness (serum K+=9.1 mmol/L).

    Reproduced with permission from Alfonzo et al.37

 Funding: This work was supported in part by funding from US Department of Defense DAMDW81XWH-05-10060, NIH R01 AG022092, and an unrestricted educational grant from Boehringer-Ingelheim Pharmaceuticals.

 Conflict of Interest: Dr White discloses that he has received research funding during the previous 12 months from the National Institutes of Health, the Catherine and Patrick Donaghue Foundation, Astra-Zeneca Pharmaceuticals, Inc, Boehringer-Ingelheim Pharmaceuticals, Inc, Novartis, Inc, and Pfizer, Inc. Dr White serves as a safety consultant to Gilead, Inc, Nicox, Inc, Palatin Technologies, Takeda Research Development Group, and Teva Neurosciences, Inc. Dr Khanna discloses he has received an unrestricted educational grant from Boehringer-Ingelheim Pharmaceuticals.

 Authorship: All authors had access to the data and played a role in writing this manuscript.

PII: S0002-9343(08)01119-4

doi: 10.1016/j.amjmed.2008.10.028

The American Journal of Medicine
Volume 122, Issue 3 , Pages 215-221 , March 2009

Article Tools

* Image Usage & Resolution